end stage renal disease;
renal cell carcinoma;
sunitinib;
DIALYSIS;
CANCER;
D O I:
10.1097/CAD.0b013e32832fffc7
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Sunitinib is a tyrosine kinase inhibitor with a low toxicity profile and proven activity against metastatic renal cell carcinoma (mRCC). However, there is very limited data on the effect of sunitinib on end stage renal disease owing to mRCC. We report our experience with the use of sunitinib in a patient with mRCC and end stage renal disease undergoing hemodialysis. Anti-Cancer Drugs 20:848-849 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.